– Company Announces Departure of Chief Business
Officer and Promotion of Pushkal Garg, M.D., to Chief Medical
Officer –
Alnylam Pharmaceuticals, Inc.
(Nasdaq:ALNY), the leading RNAi therapeutics company, today
announced that David-Alexandre "DA" Gros, M.D., Senior Vice
President and Chief Business Officer, plans to leave the company
for personal reasons. His resignation will be effective January 6,
2017, and the company will initiate a search for his replacement.
Additionally, the Company announced the promotion of Pushkal Garg,
M.D., Senior Vice President, Clinical Development, to the role of
Chief Medical Officer, reporting to Akshay Vaishnaw, Executive Vice
President of R&D.
"Alnylam is a remarkably innovative and exciting company focused
on bringing a whole new class of medicines to patients in need. I'm
grateful to have contributed during this pivotal period, and I look
forward to watching Alnylam’s continued success and growth into a
top-tier biopharmaceutical company," said Dr. Gros. "My decision to
leave is based on my personal interest to return to the West Coast
in a broader operating role."
“DA made important contributions to Alnylam and was a valued
member of our senior leadership team,” said John Maraganore, Ph.D.,
Chief Executive Officer at Alnylam. “We wish him and his family
well in their return to the West Coast.”
In his promotion to Chief Medical Officer, Dr. Garg will be
responsible for clinical development at Alnylam, leading clinical
research, clinical operations, biometrics, and medical writing
functions. He will also join the company’s Management Board.
Dr. Garg joined Alnylam in late 2014 with over 15 years of
experience in early and late-stage clinical drug development,
including at Bristol-Myers Squibb and Millennium Pharmaceuticals.
During his tenure at BMS, he was responsible for the development
and successful global approvals of several medicines in the
Immunoscience therapeutic area. He received a Bachelor of Arts from
the University of California, Berkeley, and an M.D. from the
University of California, San Francisco. He completed residency
training in Internal Medicine at UCSF, was a research fellow at
Johns Hopkins University, and served on the faculty of Harvard
Medical School and the Brigham & Women's Hospital in Boston
prior to joining industry.
"Since joining Alnylam in 2014, Pushkal has played an
instrumental role in advancing our investigational RNAi
therapeutics through the clinic and has been a key member of our
development team," said Akshay Vaishnaw, M.D., Ph.D., Executive
Vice President of R&D at Alnylam. "The promotion of Pushkal to
Chief Medical Officer is a recognition of his significant
contributions to our development activities and his broader
leadership at Alnylam and across the industry."
"I remain as excited about the opportunity to bring this new
class of therapeutics to patients now as I was the day that I
joined Alnylam, and I’m thrilled to have the opportunity to
contribute in this new role,” said Dr. Garg. “I look forward to the
continued collaboration with Akshay and the broader Alnylam
development team as we make the important transition toward a
commercial stage company.”
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
leading the translation of RNAi as a new class of innovative
medicines. Alnylam's pipeline of investigational RNAi therapeutics
is focused in 3 Strategic Therapeutic Areas (STArs): Genetic
Medicines, with a broad pipeline of RNAi therapeutics for the
treatment of rare diseases; Cardio-Metabolic Disease, with a
pipeline of RNAi therapeutics toward genetically validated,
liver-expressed disease targets for unmet needs in cardiovascular
and metabolic diseases; and Hepatic Infectious Disease, with a
pipeline of RNAi therapeutics that address the major global health
challenges of hepatic infectious diseases. In early 2015, Alnylam
launched its "Alnylam 2020" guidance for the advancement and
commercialization of RNAi therapeutics as a whole new class of
innovative medicines. Specifically, by the end of 2020, Alnylam
expects to achieve a company profile with 3 marketed products, 10
RNAi therapeutic clinical programs – including 4 in late stages of
development – across its 3 STArs. The company's demonstrated
commitment to RNAi therapeutics has enabled it to form major
alliances with leading companies including Ionis, Novartis, Roche,
Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme.
In addition, Alnylam holds an equity position in Regulus
Therapeutics Inc., a company focused on discovery, development, and
commercialization of microRNA therapeutics. Alnylam scientists and
collaborators have published their research on RNAi therapeutics in
over 200 peer-reviewed papers, including many in the world's top
scientific journals such as Nature, Nature Medicine, Nature
Biotechnology, Cell, New England Journal of Medicine, and The
Lancet. Founded in 2002, Alnylam maintains headquarters in
Cambridge, Massachusetts. For more information about Alnylam's
pipeline of investigational RNAi therapeutics, please visit
www.alnylam.com.
Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam's future
expectations, plans and prospects, its expectations regarding its
STAr pipeline growth strategy, its "Alnylam 2020" guidance for the
advancement and commercialization of RNAi therapeutics, and its
plans regarding the commercialization of RNAi therapeutics,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results and future plans may differ materially
from those indicated by these forward-looking statements as a
result of various important risks, uncertainties and other factors,
including, without limitation, Alnylam's ability to discover and
develop novel drug candidates and delivery approaches, successfully
demonstrate the efficacy and safety of its product candidates, the
pre-clinical and clinical results for its product candidates, which
may not be replicated or continue to occur in other subjects or in
additional studies or otherwise support further development of
product candidates for a specified indication or at all, actions or
advice of regulatory agencies, which may affect the design,
initiation, timing, continuation and/or progress of clinical trials
or result in the need for additional pre-clinical and/or clinical
testing, delays, interruptions or failures in the manufacture and
supply of our product candidates, obtaining, maintaining and
protecting intellectual property, Alnylam's ability to enforce its
intellectual property rights against third parties and defend its
patent portfolio against challenges from third parties, obtaining
and maintaining regulatory approval, pricing and reimbursement for
products, progress in establishing a commercial and ex-United
States infrastructure, competition from others using technology
similar to Alnylam's and others developing products for similar
uses, Alnylam's ability to manage its growth and operating
expenses, obtain additional funding to support its business
activities, and establish and maintain strategic business alliances
and new business initiatives, Alnylam's dependence on third parties
for development, manufacture and distribution of products, the
outcome of litigation, the risk of government investigations, and
unexpected expenditures, as well as those risks more fully
discussed in the "Risk Factors" filed with Alnylam's most recent
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) and in other filings that Alnylam makes
with the SEC. In addition, any forward-looking statements represent
Alnylam's views only as of today and should not be relied upon as
representing its views as of any subsequent date. Alnylam
explicitly disclaims any obligation, except to the extent required
by law, to update any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170103005401/en/
Alnylam Pharmaceuticals, Inc.Investors and MediaChristine
Regan Lindenboom, 617-682-4340orInvestorsJosh Brodsky,
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024